Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;39(3):729-739.
doi: 10.1007/s00345-020-03525-0. Epub 2021 Jan 2.

Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

Alex Z Wang  1 , Amir H Lebastchi  2   3 , Luke P O'Connor  1 , Michael Ahdoot  1 , Sherif Mehralivand  4 , Nitin Yerram  1 , Samir S Taneja  5 , Arvin K George  6 , Rafael Sanchez-Salas  7 , John F Ward  8 , Pilar Laguna  9 , Jean de la Rosette  9 , Peter A Pinto  1
Affiliations
Review

Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

Alex Z Wang et al. World J Urol. 2021 Mar.

Abstract

Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical "middle ground" in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.

Keywords: Focal therapy; MRI; prostate cancer.

PubMed Disclaimer

References

    1. Services USDoHaH. SEER Cancer Statistics Review 2018. https://seer.cancer.gov/statfacts/html/prost.html
    1. Loeb S, Gonzalez CM, Roehl KA, Han M, Antenor JA, Yap RL et al (2006) Pathological characteristics of prostate cancer detected through prostate specific antigen based screening. J Urol 175(3 Pt 1):902–906 - PubMed
    1. Ficarra V, Novara G, Rosen RC, Artibani W, Carroll PR, Costello A et al (2012) Systematic review and meta-analysis of studies reporting urinary continence recovery after robot-assisted radical prostatectomy. Eur Urol 62(3):405–417 - PubMed
    1. Pinsky PF, Parnes HL, Andriole G (2014) Mortality and complications after prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening (PLCO) trial. BJU Int 113(2):254–259 - PubMed
    1. Society AC (2019) Key Statistics for Prostate Cancer. Accessed Aug 1 2019 https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

LinkOut - more resources